
NASDAQHealthcareMedical - Specialties
Latest quote
$11.85
−$0.01 · -0.08%
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Previous close
$11.85
−$0.01 · -0.08%
Regular session · ET · Market data may be delayed.
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Day range
Current $11.85
52-week range
Current $11.85
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
56
Mixed
Risk
54
Elevated Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Day range
Current $11.85
52-week range
Current $11.85
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 |
|---|---|---|
| Revenue | 32.04M USD | 15.64M USD |
| Cost of goods sold | 6.07M USD | 3.19M USD |
| Gross profit | 25.98M USD | 12.45M USD |
| Research and development | 6.52M USD | 4.24M USD |
| Selling, general, and administrative | 65.83M USD | 32.44M USD |
| Operating expenses | 72.34M USD | 36.69M USD |
| Interest expense | 967.37K USD | 969.92K USD |
| Depreciation and amortization | 151.66K USD | 116.01K USD |
| Operating income | −46.37M USD | −24.24M USD |
| Net income | −46.5M USD | −24.6M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.67M0.00%689.3B USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM2.4M0.00%71.54B USD0.19%$256.61-2.88%
Vanguard Extended Market ETFVXF1.23M0.00%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO637.43K0.00%12.73B USD0.24%$320.43-3.57%
Vanguard Russell 2000 ETFVTWO611.06K0.00%16.8B USD0.06%$103.76-2.76%
Schwab U.S. Small-Cap ETFSCHA610.73K0.00%20.45B USD0.03%$30.51-2.83%
iShares Micro-Cap ETFIWC353.72K0.03%1.09B USD0.60%$157.87-3.19%
iShares Russell 2000 Value ETFIWN353.11K—13.05B USD0.24%$198.84-2.08%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
iShares Micro-Cap ETFIWC
iShares Russell 2000 Value ETFIWNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.